Clearside Biomedical (NASDAQ:CLSD – Get Free Report) is projected to issue its quarterly earnings data after the market closes on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $0.29 million for the quarter.
Clearside Biomedical Trading Down 7.8 %
Shares of Clearside Biomedical stock opened at $0.79 on Tuesday. The company has a fifty day moving average price of $0.97 and a 200 day moving average price of $1.06. Clearside Biomedical has a twelve month low of $0.77 and a twelve month high of $2.12. The stock has a market cap of $60.11 million, a price-to-earnings ratio of -1.76 and a beta of 2.22.
Analysts Set New Price Targets
CLSD has been the subject of a number of research reports. StockNews.com raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Thursday, December 12th. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Wednesday, November 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Clearside Biomedical presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.33.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Further Reading
- Five stocks we like better than Clearside Biomedical
- Top Biotech Stocks: Exploring Innovation Opportunities
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Investing in Travel Stocks Benefits
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- The Basics of Support and Resistance
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
